Cancers, a group of multifactorial complex diseases, are generally caused by mutation of multiple genes or dysregulation of gene interactions. Applying machine learning methods to microarray gene expression profiles for disease classification is a popular method to predict disease state or outcome. Traditional computational methods that detect genes differentially expressed between cancer and normal samples are ineffective in independent cohorts of patients. However, current methods consider pathways as simple gene sets and include pathway topological information but ignore significant individual genes and interactions between genes, which are essential to infer a more robust pathway activity. In this study, we proposed a novel approach to describe the activity of a pathway that incorporates both the differential expression degree of genes between the case and control and the interaction strength between genes. We applied the method to the classifications of seven cancers. Within-dataset experiments and cross-dataset experiments demonstrated that our novel method achieved robust and superior performance when compared to the five existing methods.
I. INTRODUCTION
Analyses of genome-wide expression profiles can aid in understanding the mechanisms of biological processes, identifying biomarkers for cancers and designing therapeutic strategies [1] - [8] . One important challenge in clinical cancer research is accurately predicting disease states and treatment responses of a patient based on the expression of genes. An increasing number of disease markers have been identified through the analysis of genome-wide expression profiles [9] - [12] . One direct approach is to score each individual gene based on its power to discriminate samples between case and control [13] - [16] . However, the gene markers identified in one dataset usually share little overlap with those obtained in other datasets due to noise in microarray data and cellular heterogeneity within tissues. In addition, precise classification is also impeded by the so-called ''large p small n''
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property, whereby the number of samples (or instances) is typically several orders of magnitude smaller than the number of genes (or features), making it difficult to extract reliable information from transcriptome profiles [17] , [18] . All of these factors often lead to gene markers discovered in one dataset failing to be predictive of the same disease phenotype in other independent datasets.
As gene products are known to function coordinately in functional modules or signaling cascades, perturbed highlevel functional modules may be more consistent with the disease state of interest than individual genes [19] . Thus, integrating gene expression data with available large proteinprotein interaction (PPI) networks or known pathways may identify more reproducible biomarkers [20] - [26] . Networklevel analyses can be categorized as PPI-based or pathwaybased methods. Both approaches consist of three steps: first, search potential subnetworks or pathways and sort them according to their discriminative score; second, select feature subnetworks or pathways; finally, design a classifier according to the activity of the selected subnetworks or pathways. Chuang et al. proposed a method to search subnetwork markers based on mutual information or t-scores measuring the association between the marker's activity and class label [27] . Su et al. searched for the top discriminative linear paths using dynamic programming in a PPI network. The discriminative score of a path incorporated both the t-test statistics of the member genes and the correlation between their expression values [28] . The activity of a subnetwork was inferred by combining the normalized log-likelihood ratios (LLRs) of its member genes. In pathway-based analyses, the discriminative score of a pathway is defined as the t-test statistic score for the member genes. The main difference between these approaches lies in how they define pathway activity. For example, Guo et al. estimated the pathway activity using the mean or median of the gene expression values of the member genes [29] . In a PCA approach, Bild et al. used the first basis vector to weight the expression values of the member genes in a pathway [30] . Lee et al. proposed to infer the pathway activity by condition-responsive genes method [31] . Liu et al. proposed a directed random walk (DRW) to mine the topological importance of genes in a pathway network. The activity of a pathway was defined by the weighted expression values of the member genes [32] . They also extended this method to include both genomic and metabolic data [33] - [36] . Recently, this topological approach was applied to predict breast cancer survival outcomes [37] .
Although previous methods have achieved great progress in cancer classification based on the activity of pathways or subnetworks, the activity of the pathway or subnetwork was defined as a simple summary of expression values of the member genes, which could not reflect the interactions between genes at the network level. However, it is the interaction between genes that shifts the direction of biological signaling cascades. In order to model their effect, Tarca et al. proposed a signaling pathway impact analysis (SPIA) method to model the impact of perturbed upstream genes on their downstream partners [38] .
In this study, we proposed a method to quantify pathway activity using both genes and their interactions (PAGI). We first constructed a pathway expression profile matrix that includes both genes and their interactions. Then the first principle component of the expression profile matrix was calculated. Finally, the activity of the pathway was derived based on the product of the first component and their corresponding expression values. Both within-dataset experiments and cross-dataset experiments demonstrated that the proposed PAGI method was more accurate and more robust than the DRW, PAC, mean, median, and gene methods on datasets for seven different cancers. Table 1 lists the 22 microarray datasets for seven cancers downloaded from the NCBI Gene Expression Omnibus (GEO) database [39] . In these datasets, 9 datasets were studied in the within-dataset experiment and were used as training dataset in cross-dataset experiment: GSE10072 for lung cancer [40] , GSE13911 for stomach cancer [41] , GSE17856 for liver cancer [42] , GSE5364 for thyroid cancer [42] , GSE15641 and GSE17895 for kidney cancer [43] , [44] , GSE3494 and GSE1456 for breast cancer [34] , [45] , and GSE8511 for prostate cancer [46] . The other 13 datasets were used for validation in cross-dataset experiments. In the breast cancer datasets, patients died within 5 years were defined as negative samples, while the remaining patients were considered positive samples (patients with a survival time of 55 years without any reported events were excluded). The prostate cancer datasets contained three types of samples: Benign, PCA, and Mets, and we built two classifications to classify Benign and PCA samples as well as PCA and Mets samples. All pathway information was downloaded from the KEGG database [47] .
II. DATASETS

III. METHODS
The pathway is a gene network that includes both genes and their interactions to fulfill some specific biological functions. Our motivation is that the activity of a pathway should reflect the following three factors: (1) the degree of the differential expression of genes between case and control group; (2) the correlation between a gene's expression and the class label (control, case, metastatic or non-metastatic); (3) their interaction strength between genes connected in a pathway. Based on these considerations, we proposed a new way to infer the activity of a pathway. Fig. 1 displays the main workflow of the proposed method PAGI in this paper.
Given a pathway P = {G, E} that includes genes G = {g 1 , g 2 , . . . , g n } and interactions E = {e 1 , e 2 , . . . , e l }, we first constructed a new expression profile matrix including both genes and their corresponding interactions in a pathway network. The expression of a gene g i in sample k is transformed as
where t i is the t-score of g i calculated from a two-tailed t-test between two phenotypes, and ρ i is the Pearson correlation coefficient between gene g i and class label c. After this transformation, Z ij actually represents a weighted expression of gene g i in sample k which reflects both the differential expression degree of gene g i and its correlation with the phenotype. The more differentially expressed, the larger Z ij . And the larger its correlation with the phenotype, the larger Z ij . Similarly, the expression profile of their interaction of gene pair g i and g j in sample k is defined as
where ρ ij is the Pearson correlation coefficient between genes g i and g j , β ij indicates the interaction type between gene g i and g j (1 for activation or −1 for inhibition). Obviously, the larger the interaction strength, the larger e ijk . The expression profile of a pathway P can then be denoted by a · (n + 1) × m matrix M p , where rows represent the genes or their interactions and columns represent samples. Secondly, we then applied the principal component analysis (PCA) on the matrix M p to infer the activity score a pk of pathway P in sample k as:
where w i and w j are the corresponding component in the first eigenvector for gene i and interaction j respectively.
IV. RESULTS
In this section, we used the logistic regression model to evaluate the performance of gene method in [28] , mean and median method in [29] , PAC method in [30] , DRW method in [31] and the proposed PAGI method. The average area under ROC curve (AUC) [48] , [49] and the corresponding standard deviation (SD) by five-fold cross-validation [50] , [51] over 1000 times were calculated for the six methods [52] - [58] . The experiment setting was the same as in [32] , [35] for the DRW, PAC, mean, median, and gene methods. For the gene method, the top 50 discriminative gene markers were chosen as the candidate features in order to maintain an identical maximum number of features as in [28] . In cross-dataset experiments, the first dataset was used as the training set, and other independent datasets were used as the test set.
A. CLASSIFICATION PERFORMANCE ON WITHIN-DATASET EXPERIMENTS Fig. 2 . shows the average AUC and SD of the six methods on the 10 within-datasets. The average AUC of all the six methods were about more than 0.8 except on the two breast cancer datasets. First, PAGI achieved the largest AUC in all cancer datasets except the lung cancer dataset GSE10072 where it was slightly less than that of DRW. Especially, compared with other methods, PAGI sharply improved the AUC in four datasets GSE17895, GSE3494, GSE1456 and GSE8511. Secondly, the average SD of PAGI was the least except in three datasets GSE10072, GSE13911 and GSE3494 where it is the second least in the six methods. These two observations demonstrated that PAGI had the best overall classification performance and stability on within-datasets experiments. 
B. CLASSIFICATION PERFORMANCE ON CROSS-DATASET EXPERIMENTS
To evaluate the generalization ability of the six methods, we carried out cross-dataset experiments using 18 additional independent datasets. Fig. 3 shows their average AUC and SD on these independent datasets. First, as expected, the average AUC for each method varied sharply in different independent datasets except the lung cancer and liver cancer datasets. Apart from the heterogeneity and noises inherent in these datasets, how to extract the internal characteristic is the key to deal with this reproducibility issue. Secondly, PAGI achieved the largest average AUC in all datasets except the independent lung cancer dataset GSE19188 where it was slightly less than that of DRW. Especially, PAGI sharply improved the AUC in at least one independent datasets in the six cancers except for lung cancer. Thirdly, the average SD of PAGI was the least except in one lung cancer dataset GSE19188 where it is the second least in the six methods. These observations demonstrated that PAGI also had the best overall classification performance and stability on cross-datasets experiments which were consistent with the with-datasets experiments. They indicated that the PAGI-based pathway activities were less sensitive to different cohorts of patients and microarray platforms and were more reliable in predicting clinical outcomes in practice. A potential reason may be that the PAGI incorporates both the importance of genes based on their differential expressions and topological interaction information to build the classifier [59] .
C. ROBUSTNESS OF RISK-ACTIVE PATHWAYS
In cancer studies, many pathways, such as the MAPK signaling pathway, p53 signaling pathway, and pathway in cancer, have been found highly related to the development of various cancers [32] , [60] . classification, the perturbation of gene expressions in these pathways should provide enough information.
In this paper, the proposed PAGI only used one of them as a feature to build classifier. The performance of PAGI was actually the best AUC obtained by one of the 18 pathways. The best feature pathway for different cancer datasets might be different. For example on within-datasets, insulin signaling pathway was the best pathway for lung cancer, RNA transport for stomach cancer, adipocytokine signaling pathway for liver cancer, p53 signaling pathway for thyroid, MAPK signaling pathway and regulation of actin cytoskeleton for the two kidney cancer datasets respectively, MAPK signaling pathway and regulation of actin cytoskeleton for the two breast cancer datasets respectively, and MAPK signaling pathway for prostate cancer. On cross-datasets, the best pathway for different cancer datasets was also different.
For a given dataset, we found that the results of PAGI by most of the 18 pathways were very close to the best performance on both within-datasets and cross-datasets. Fig. 4 . shows the average AUC of PAGI by the five pathways with the largest degree in Table 2 . The close performance by these pathways demonstrated that the proposed activity score could provide highly discriminative information for cancer classification only by one pathway. This indicates that the newly proposed pathway activity might capture more of the essential features of various cancers than that used by mean, median, PAC and DRW methods whose best performance was derived from a selected pathway set.
MAPK signaling pathway is an important known cancer pathway connected with 69 other pathways. Our results showed that the average AUC by this pathway was the largest both in the within-datasets and cross-datasets of the seven cancers. That is, we could reach a relative satisfactory classification result by the MAPK pathway without feature selection. Apart from it connects with many important pathways, another reason may be MAPK signaling pathway shared many important genes with other pathways.
D. SIGNIFICANT DIFFERENCE OF GENES AND THEIR INTERACTIONS BETWEEN TWO PHENOTYPES
To mine the important information for medical diagnosis, we further analyzed the significant difference of genes and their interactions in pathway between two phenotypes. We acquired 10(42) genes and 56(361) interactions with significant difference between the two phenotypes in the ''Benign-PCA'' case (the ''PCA-Mets'' case). Fig.5 show the heat maps (A and B) of the significant difference of genes and interactions in the ''Benign-PCA'' case and the ''PCA-Mets'' case. On one side these individual genes such as NGFR and FLT1 have small difference between two phenotypes, but their interactions with other genes had significant difference between two phenotypes. On other side, some individual genes such as NGF and FGFR2 had small difference between two phenotypes, but their interactions had outstanding difference when they interacted with each other.
V. CONCLUSION
How to accurately discriminate various cancers is a crucial issue for clinical treatment. As genes are corporately interacted with each other to fulfill specific biological functions, the activities of pathways become a potential feature for cancer classification. In this paper, we proposed a novel method to describe pathway activity which incorporates both the genes' activity and their interactions. Specifically, in order to extract the essential features for a disease state, we first transformed the expression of a gene to a weighted activity based on their differential expression degree between case and control and their correlation with the phenotype. Then we defined the activity of a gene pair in a pathway by their interaction strength. Finally, the activity score of a pathway for a sample was calculated as an arithmetic weighted activity of genes and gene pairs by the first eigenvector of PCA on the expression profile matrix of the pathway.
We studied the performance of the new proposed method PAGI on datasets of seven cancers, which included 10 withindataset experiments and 20 cross-dataset experiments. Results on these datasets demonstrated that the proposed PAGI performed better and was more robust than the other five methods. Furthermore, the proposed PAGI could achieve the best performance by using only one pathway while the other methods might need to select the best pathway set. Results on the 18 known cancer-related pathways showed that the performance of most pathways was very close to the best performance. This indicated that the proposed PAGI was even robust on many cancer-related pathways. Additionally, we found that the proposed PAGI could achieve a satisfactory performance for all datasets by the MAPK signaling pathway. Although PAGI had above advantages, we believe there is still room to study pathway activity more effectively, by employing new generation machine learning [61] - [67] and computational intelligence algorithms [68] - [73] . 
